脑转移瘤放疗中医师报告与患者报告结局的不一致性:前瞻性NeuroPRO研究
84%(27/32)共享症状中患者报告评分高于医师报告,提示医师系统性低估症状负担,心理与神经症状一致性较差,胃肠道及治疗相关症状一致性较高。
要点
- 脑转移放疗中84%共享症状被医师低估,心理领域尤为明显。
- 医师与患者报告一致性因症状类型差异大,需常规整合PRO。
- 患者报告总体健康状况稳定且决策后悔低。
核心结论
- 仅凭医师评估会系统性低估脑转移放疗患者的症状负担,尤其心理领域及难以归因于放疗的躯体症状。
研究设计与样本
- 放疗完成后另用渥太华决策后悔量表评估决策后悔,采用Gwet AC2量化机会校正一致性,并用双因素方差分析和Bland-Altman分析纵向差异与一致性界限。
主要发现
- 32个共享症状中27个(84%)PRO评分高于CRO评分,提示医师系统性低估症状。
- 心理与神经症状一致性为一般至中等(担忧AC2=0.30;抑郁AC2=0.39;嗜睡AC2=0.44),胃肠道及治疗相关症状一致性为显著至几乎完全(呕吐AC2=0.96;癫痫发作AC2=0.94;恶心AC2=0.92)。
- 单条目差异最大为呼吸困难(偏倚1.00;95% LoA 0.85-1.14;组间p<0.001)、失眠(偏倚0.76;95% LoA 0.22-1.29;组间p<0.001)和抑郁(偏倚0.75;95% LoA 0.39-1.12;组间p<0.001)。
- 患者报告总体健康状况在放疗后保持稳定,决策后悔低。
临床怎么用
- 在神经肿瘤多学科诊疗中常规整合患者报告结局,以改善症状识别和以患者为中心的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinician-reported outcomes (CROs) remain a central component of side effect assessment in radiotherapy, while patient-reported outcomes (PROs) are increasingly being integrated into standard practice to better capture the subjective symptom burden experienced by patients. Agreement between CRO and PRO has not been prospectively studied in patients undergoing radiotherapy for brain metastases. METHODS: NeuroPRO was a prospective longitudinal cohort study enrolling patients receiving radiotherapy for brain metastases. CROs were assessed using predefined CTCAE (version 5.0) items, while PROs were collected using the EORTC QLQ-C30 and BN20 at baseline, end of treatment, and first follow-up. Upon completion of radiotherapy, decision regret was evaluated additionally using the Ottawa Decision Regret Scale. Chance-corrected agreement between CRO and PRO was quantified for each item using Gwet's second-order agreement coefficient (AC2). Longitudinal differences were additionally explored using two-way ANOVA and agreement was further characterized using Bland-Altman analyses with calculation of limits of agreement (LoA). RESULTS: Sixty-three patients were included, completing 278 questionnaires and yielding 4448 matched CRO-PRO item comparisons. Across 27 of 32 shared symptoms (84%), PRO scores were higher than CRO scores, indicating systematic symptom underestimation by clinicians. Chance-corrected agreement (Gwet's AC2) was fair to moderate for psychological and neurological symptoms (worry AC2 = 0.30; depression AC2 = 0.39; drowsiness AC2 = 0.44) and substantial to almost perfect for gastrointestinal and treatment-related symptoms (vomiting AC2 = 0.96; seizures AC2 = 0.94; nausea AC2 = 0.92), corroborating the pattern observed with mean-based comparisons. The largest single-item discrepancies were observed for dyspnea (bias 1.00; 95% LoA 0.85-1.14; group p < 0.001), insomnia (bias 0.76; 95% LoA 0.22-1.29; group p < 0.001), and depression (bias 0.75; 95% LoA 0.39-1.12; group p < 0.001). Symptom clustering demonstrated higher agreement for directly treatment-related effects and physical functioning, whereas agreement was substantially lower for emotional and cognitive domains. Patient-reported global health status remained stable after radiotherapy, and decision regret was low. CONCLUSION: Sole clinician assessment systematically underestimates symptom burden in patients undergoing radiotherapy for brain metastases, particularly within psychological domains and somatic symptoms not readily attributable to radiotherapy. These findings reveal a structural perception gap and support the routine integration of PROs into interdisciplinary neuro-oncologic care to enhance symptom recognition and promote patient-centered management (DRKS00031480).
引用
- Dejonckheere CS, Layer YL, Potthoff AL, et al. Discordance between clinician- and patient-reported outcomes during radiotherapy for brain metastases: the prospective NeuroPRO study. Clin Transl Radiat Oncol. 2026. PMID: 42751485. doi:10.1016/j.ctro.2026.101283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。